{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:32:43Z","timestamp":1794047563779,"version":"4.8.0"},"reference-count":0,"publisher":"Ferrata Storti Foundation (Haematologica)","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Asparaginase-based regimens and anti-PD-1 therapies have significantly improved survival in patients with extranodal natural killer\/T-cell lymphoma (ENKTL) and are now increasingly incorporated into earlier treatment lines. However, clinical outcomes for patients with dual resistance to asparaginase and PD-1 inhibitors remain poorly defined. We conducted a multicenter retrospective study of 61 patients with dual resistance from a cohort of 900 ENKTL patients across 12 academic centers in China. Among 61 patients, median overall survival from initial diagnosis (OS-1) was 21.9 months (95% CI: 14.7\u201343.1). After the onset of dual resistance, the median post-resistance survival (OS-2) was 4.9 months (95% CI: 2.8\u20139.9). Rechallenge with asparaginase-based regimens or anti-PD-1 agents resulted in only limited benefit, yielding median progression-free survival (PFS) of 3.2 months (95% CI: 1.4\u20135.0) and 2.7 months (95% CI: 2.1\u20133.3), respectively. Chidamide-containing regimens were associated with a significantly longer OS-2 compared to regimens without chidamide (HR, 0.46; 95% CI: 0.24\u20130.88; P = 0.019). Other novel agents, including inhibitors of XPO1, PI3K, and JAK1, along with brentuximab vedotin, did not demonstrate a significant survival benefit in patients with dual-resistant ENKTL. This is the first comprehensive analysis of dual-resistant ENKTL, revealing poor prognosis and suggesting a potential signal of benefit associated with chidamide-containing regimens.<\/jats:p>","DOI":"10.3324\/haematol.2026.300670","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T07:34:26Z","timestamp":1783582466000},"source":"Crossref","is-referenced-by-count":0,"title":["Dual resistance to asparaginase and PD-1 blockade in extranodal natural killer\/T-cell lymphoma: dismal outcomes from a multicenter cohort"],"prefix":"10.3324","author":[{"given":"Ran","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuzhang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiran","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lvwen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haorui","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongming","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinning","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiyang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2026,7,9]]},"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/14275\/80566","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/14275\/80566","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:14:42Z","timestamp":1794046482000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/14275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":0,"URL":"https:\/\/doi.org\/10.3324\/haematol.2026.300670","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,9]]}}}